Dergiler / Clinical and Experimental Health Sciences / 2023 / Cilt: 13 Sayı: 3

Nasal Sprays Containing Mometasone Furoate Can Be Used Prophylactically in COVID-19 Infection and Related Smell Disorders

Sayfa
537–540
Yayın Tarihi
2023-09-11
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusions: The role of these molecules in the treatment of acute smell disorders associated with COVID-19 infection and their antiviral effects on coronavirus should be investigated by conducting extensive scientific studies on the subject.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: We aimed to emphasize the possible beneficial effects of intranasal sprays containing mometasone furoate, especially for preventive treatment or supportive treatment in patients with olfactory disorders due to damage to the olfactory area, or for regular use in healthcare workers with a high risk of close contact.
📊
Temel Bulgular & Veri:Methods: Preventive and therapeutic scientific studies are continuing around the world for viral spread and viral damage associated with the Coronavirus disease 2019 (COVID-19) pandemic.
💡
Sonuç & Katkı:Conclusions: The role of these molecules in the treatment of acute smell disorders associated with COVID-19 infection and their antiviral effects on coronavirus should be investigated by conducting extensive scientific studies on the subject.
🔬Tür:Araştırma Makalesi
📍Kapsam:2019 Verileri
⚙️Değişkenler:Anosmia · Coronavirus · Mometasone furoate

Abstract

Objective: We aimed to emphasize the possible beneficial effects of intranasal sprays containing mometasone furoate, especially for preventive treatment or supportive treatment in patients with olfactory disorders due to damage to the olfactory area, or for regular use in healthcare workers with a high risk of close contact. Methods: Preventive and therapeutic scientific studies are continuing around the world for viral spread and viral damage associated with the Coronavirus disease 2019 (COVID-19) pandemic. We investigated the attachment of the COVID-19 virus in the nose and entry into the body with the crystal structure of the spike and Angiotensin-Converting Enzyme 2 (ACE-2) proteins, a molecular docking study. This scientific study is the first in-silico study to investigate the possible antiviral effects of Mometasone furoate molecules on spike protein and to show the antiviral effect of mometasone furoate on COVID-19. Results: We think that nasal sprays containing mometasone furoate can be used prophylactically in patients with COVID-19 infection due to its antiviral effect, and it may be beneficial to use sprays containing mometasone furoate before the symptoms of upper respiratory tract infection begin in patients. Conclusions: The role of these molecules in the treatment of acute smell disorders associated with COVID-19 infection and their antiviral effects on coronavirus should be investigated by conducting extensive scientific studies on the subject.

🔖

Bu Makaleye Atıf Yap

ENÖZ, M., ÖZDEMİR, M., YALCİN, B. (2023). Nasal Sprays Containing Mometasone Furoate Can Be Used Prophylactically in COVID-19 Infection and Related Smell Disorders. Clinical and Experimental Health Sciences, Cilt: 13 Sayı: 3, 537–540. https://ajindex.com/articles/961652

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Zitt M, Kosoglou T, Hubbell J. Mometasone Furoate Nasal Spray. Drug-Safety 2007;30:317–326.
  2. Onrust Susan V, Lamb Harriet M. Mometasone Furoate. Drugs 1998;56:725–745.
  3. Baldwin Claudine M, Scott Lesley J. Mometasone Furoate. Drugs 2008;68: 1723–1739.
  4. Robert Davies J, Harold Nelson S. Once-daily mometasone furoate nasal spray: Efficacy and safety of a new intranasal Glucocorticoid for Allergic Rhinitis Clin Ther 1997;19(1):27-38.
  5. Kasiri H, Rouhani N, Salehifar E, Ghazaeian M, Fallah S. Mometasone furoate nasal spray in the treatment of patients with COVID-19 olfactory dysfunction: A randomized, double blind clinical trial. Int. Immunopharmacol 2021;98:107871. Abdelalim Ahmed A, Mohamady Abdelaal A, Elsayed Rasha A, Elawady Mona A, Ghallab Abdelhakim F. Corticosteroid nasal spray for recovery of smell sensation in COVID-19 patients: A randomized controlled trial. Am J Otolaryngol 2021;42(2):102884. Trott O, Olson Arthur J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J Comput Chem 2010;31(2):455-461.
  6. Eberhardt J, Santos-Martins D, Tillack Andreas F, Forli, S. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. J Chem Inf Model 2021;61:3891-3898.
  7. Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhang Q, Shi X, Wang Q, Zhang L, Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020;581(7807):215-220.
  8. Xiaoming Sean C, Matthew C, Curtis H, Prudence B. Solid state characterization of mometasone furoate anhydrous and monohydrate forms. J Pharm Sci 2005;94(11):2496-2509. BIOVA Dassault Systèmes, Discovery Studio Visualizer 2021,
  9. San Diego, CA, USA, 2017.
  10. Pettersen Eric F, Goddard Thomas D, Huang Conrad C, Couch Gregory S, Greenblatt Daniel M, Meng Elaine C, Ferrin Thomas E. UCSF Chimera—a visualization system for exploratory research and analysis. J Comput Chem 2004;25(13):1605-12.
  11. Matsuyama S, Kawase M, Nao N, Shirato N, Ujike M, Kamitani W, Shimojima M, Fukushi S. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. J Virol 2020;95(1):e01648-20. Webster Katie E, O'Byrne L, MacKeith S, Philpott C, Hopkins C, Burton Martin J. Interventions for the prevention of persistent post-COVID-19 olfactory dysfunction. Cochrane Database Syst Rev 2021;22;7(7):CD013877. Carrillo-Larco Rodrigo M, Altez-Fernandez C. Anosmia and dysgeusia in COVID-19: A systematic review. Well